Literature DB >> 24508625

Harmonization of growth hormone measurement results: the empirical approach.

H A Ross1, E W G M Lentjes2, P M M Menheere3, C G J Sweep4.   

Abstract

Growth hormone (hGH) is a measurand belonging to ISO category 4, indicating intrinsic unavailability of a reference measurement procedure and primary standard material. Large between-method differences have been raising confusion, especially in the interpretation of results of stimulation tests for exclusion of juvenile growth hormone deficiency. Within the framework of the external quality assessment scheme (EQAS) of the SKML (Dutch Foundation for Quality Assessment in Clinical Laboratories), attempts to reduce between-method variation of hGH measurements have been made, starting in 1994 with an inter-laboratory comparison of 9 different immunoassays by using a panel of sera and standard materials available at that time. Methods appeared to differ from each other largely in a systematic, sample-independent manner. These systematic differences are reflected in the hGH measurement results obtained in commutable sera. A commutable serum pool was introduced as a consensus reference material, permitting correction of each method's results to a common scale. Pair wise comparisons ("twin studies") were carried out to investigate and corroborate the effectiveness of this material for harmonization. A significant reduction of the between-laboratory coefficient (CV) of variation from 22 to 9.0% was attained.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Commutability; Growth hormone; Harmonization

Mesh:

Substances:

Year:  2014        PMID: 24508625     DOI: 10.1016/j.cca.2014.01.008

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  4 in total

1.  IFCC Working Group Recommendations for Correction of Bias Caused by Noncommutability of a Certified Reference Material Used in the Calibration Hierarchy of an End-User Measurement Procedure.

Authors:  W Greg Miller; Jeffrey Budd; Neil Greenberg; Cas Weykamp; Harald Althaus; Heinz Schimmel; Mauro Panteghini; Vincent Delatour; Ferruccio Ceriotti; Thomas Keller; Douglas Hawkins; Chris Burns; Robert Rej; Johanna E Camara; Finlay MacKenzie; Eline van der Hagen; Hubert Vesper
Journal:  Clin Chem       Date:  2020-06-01       Impact factor: 8.327

2.  Low sclerostin levels after long-term remission of acromegaly.

Authors:  Kim M J A Claessen; Iris C M Pelsma; Herman M Kroon; Antoon H van Lierop; Alberto M Pereira; Nienke R Biermasz; Natasha M Appelman-Dijkstra
Journal:  Endocrine       Date:  2021-08-26       Impact factor: 3.633

3.  Low prevalence of neuropathic-like pain symptoms in long-term controlled acromegaly.

Authors:  Victoria R van Trigt; Iris C M Pelsma; Herman M Kroon; Alberto M Pereira; Coen van der Meulen; Margreet Kloppenburg; Nienke R Biermasz; Kim M J A Claessen
Journal:  Pituitary       Date:  2021-10-23       Impact factor: 4.107

4.  Clinical and radiographic assessment of peripheral joints in controlled acromegaly.

Authors:  Iris C M Pelsma; Herman M Kroon; Victoria R van Trigt; Alberto M Pereira; Margreet Kloppenburg; Nienke R Biermasz; Kim M J A Claessen
Journal:  Pituitary       Date:  2022-06-20       Impact factor: 3.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.